BRPI0407854A - composição de vacina e método para o tratamento de um paciente que requer um reforço de sua resposta imunológica - Google Patents

composição de vacina e método para o tratamento de um paciente que requer um reforço de sua resposta imunológica

Info

Publication number
BRPI0407854A
BRPI0407854A BRPI0407854-3A BRPI0407854A BRPI0407854A BR PI0407854 A BRPI0407854 A BR PI0407854A BR PI0407854 A BRPI0407854 A BR PI0407854A BR PI0407854 A BRPI0407854 A BR PI0407854A
Authority
BR
Brazil
Prior art keywords
vaccine composition
vssp
patient
boost
treating
Prior art date
Application number
BRPI0407854-3A
Other languages
English (en)
Inventor
Luis Enrique Fernandez Molina
Circe Mesa Pardillo
Original Assignee
Centro Inmunologia Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centro Inmunologia Molecular filed Critical Centro Inmunologia Molecular
Publication of BRPI0407854A publication Critical patent/BRPI0407854A/pt
Publication of BRPI0407854B1 publication Critical patent/BRPI0407854B1/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/385Haptens or antigens, bound to carriers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/001169Tumor associated carbohydrates
    • A61K39/001171Gangliosides, e.g. GM2, GD2 or GD3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/095Neisseria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55555Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)

Abstract

"COMPOSIçãO DE VACINA E MéTODO PARA O TRATAMENTO DE UM PACIENTE QUE REQUER UM REFORçO DE SUA RESPOSTA IMUNOLóGICA". Descreve-se composições vacinais em que se combina gangliosídeos e o complexo de proteínas de membrana externa (CPME) de N. meningitidis para formar proteoliposomas de tamanho muito pequeno (sigla em inglês: VSSP) que se destinam à administração subcutânea. Estas composições não requerem o emprego adicional de adjuvantes. As composições descritas permitem tratamentos imunológicos com gangliosídeos, particularmente N-AcGM3/VSSP e N-GcGM3/VSSP, que apresentam vantagens por serem menos agressivas no lugar da injeção, e podem ser utilizadas de maneira mais simples e com menos desconforto para os pacientes.
BRPI0407854-3A 2003-02-27 2004-02-27 Composição de vacina que compreende uma solução ou dispersão aquosa de um ou mais gangliosídeos incluídos em vssp BRPI0407854B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CU47-2003 2003-02-27
CU20030047A CU23257A1 (es) 2003-02-27 2003-02-27 COMPOSICIONES VACUNALES A BASE DE GANGLIOSIDOS PARA LA ADMINISTRACION SUBCUTáNEA
PCT/CU2004/000003 WO2004075811A2 (es) 2003-02-27 2004-02-27 Composiciones vacunales a base de gangliósidos para administración subcutánea

Publications (2)

Publication Number Publication Date
BRPI0407854A true BRPI0407854A (pt) 2006-02-14
BRPI0407854B1 BRPI0407854B1 (pt) 2019-02-26

Family

ID=40091613

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0407854-3A BRPI0407854B1 (pt) 2003-02-27 2004-02-27 Composição de vacina que compreende uma solução ou dispersão aquosa de um ou mais gangliosídeos incluídos em vssp

Country Status (36)

Country Link
US (1) US8591917B2 (pt)
EP (1) EP1604683B1 (pt)
JP (1) JP4729475B2 (pt)
KR (1) KR100703570B1 (pt)
CN (1) CN100418576C (pt)
AR (1) AR043377A1 (pt)
AT (1) ATE353668T1 (pt)
AU (1) AU2004216554B2 (pt)
BR (1) BRPI0407854B1 (pt)
CA (1) CA2535214C (pt)
CL (1) CL2004000374A1 (pt)
CR (1) CR7965A (pt)
CU (1) CU23257A1 (pt)
CY (1) CY1106668T1 (pt)
DE (1) DE602004004768T2 (pt)
DK (1) DK1604683T3 (pt)
EA (1) EA008905B1 (pt)
EC (1) ECSP055978A (pt)
EG (1) EG26446A (pt)
ES (1) ES2280948T3 (pt)
GE (1) GEP20074120B (pt)
HR (1) HRP20050763A2 (pt)
IL (1) IL170355A (pt)
LT (1) LT5351B (pt)
LV (1) LV13400B (pt)
MY (1) MY139811A (pt)
NZ (1) NZ541952A (pt)
PE (1) PE20040955A1 (pt)
PT (1) PT1604683E (pt)
RS (1) RS20050664A (pt)
SI (1) SI1604683T1 (pt)
TN (1) TNSN05209A1 (pt)
TW (1) TWI344372B (pt)
UA (1) UA80859C2 (pt)
UY (1) UY28207A1 (pt)
WO (1) WO2004075811A2 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU24534B1 (es) * 2017-11-06 2021-07-02 Ct Inmunologia Molecular Adyuvantes nano-particulados que contienen variantes sintéticas del gangliósido gm3
CU20170173A7 (es) 2017-12-27 2019-11-04 Ct Inmunologia Molecular Nano-partículas que contienen el gangliósido gm3 como inmunomoduladoras

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4965198A (en) 1985-12-24 1990-10-23 Konica Corporation Monoclonal antibody and method of manufacturing hybridoma producing the same
US6149921A (en) * 1993-12-29 2000-11-21 Centro De Inmunologia Molecular Vaccine compositions for eliciting an immune response against N-acetylated gangliosides and their use for cancer treatment
CU22420A1 (es) * 1993-12-29 1996-01-31 Centro Inmunologia Molecular Composicion vacunal para el desarrollo de una respuesta contra gangliosidos n glicolilados y su uso para el tratamiento del cancer
PE20020572A1 (es) * 2000-12-06 2002-07-31 Centro Inmunologia Molecular Preparaciones para potenciar la inmunogenicidad de antigenos poco inmunogenicos
US20030108574A1 (en) * 2001-08-21 2003-06-12 Jennings Harold J. Carbohydrate-based whole cell cancer vaccines

Also Published As

Publication number Publication date
WO2004075811A2 (es) 2004-09-10
DK1604683T3 (da) 2007-06-11
ECSP055978A (es) 2006-01-16
CY1106668T1 (el) 2012-05-23
JP2006519186A (ja) 2006-08-24
PE20040955A1 (es) 2005-02-03
US8591917B2 (en) 2013-11-26
SI1604683T1 (sl) 2007-08-31
EA200501367A1 (ru) 2006-02-24
UY28207A1 (es) 2004-09-30
NZ541952A (en) 2008-06-30
LT5351B (lt) 2006-07-25
LV13400B (en) 2006-05-20
LT2005087A (en) 2006-04-25
CN100418576C (zh) 2008-09-17
JP4729475B2 (ja) 2011-07-20
CA2535214C (en) 2012-01-10
HK1087630A1 (zh) 2006-10-20
CL2004000374A1 (es) 2005-05-06
ES2280948T3 (es) 2007-09-16
CA2535214A1 (en) 2004-09-10
AU2004216554A1 (en) 2004-09-10
IL170355A (en) 2010-05-31
KR20060003857A (ko) 2006-01-11
CN1753691A (zh) 2006-03-29
GEP20074120B (en) 2007-05-25
RS20050664A (sr) 2007-11-15
EP1604683A2 (en) 2005-12-14
AR043377A1 (es) 2005-07-27
CR7965A (es) 2008-10-29
HRP20050763A2 (en) 2006-06-30
CU23257A1 (es) 2008-01-24
KR100703570B1 (ko) 2007-04-09
EP1604683B1 (en) 2007-02-14
TWI344372B (en) 2011-07-01
BRPI0407854B1 (pt) 2019-02-26
UA80859C2 (en) 2007-11-12
ATE353668T1 (de) 2007-03-15
AU2004216554B2 (en) 2010-05-20
WO2004075811A3 (es) 2004-10-14
TNSN05209A1 (en) 2007-06-11
PT1604683E (pt) 2007-05-31
US20070148181A1 (en) 2007-06-28
DE602004004768T2 (de) 2007-10-11
MY139811A (en) 2009-10-30
EA008905B1 (ru) 2007-08-31
DE602004004768D1 (de) 2007-03-29
EG26446A (en) 2013-11-07

Similar Documents

Publication Publication Date Title
RU2434640C2 (ru) Лечение метастатического рака молочной железы
BR0212999A (pt) novas composições imunogênicas para a prevenção e tratamento de doença meningocócica
BR0210804A (pt) Vacinação de dose única com mycoplásma hyopneumoniae
BRPI0409459A (pt) novas composições imunogênicas para a prevenção e tratamento de doença meningocócica
PE20040562A1 (es) Vacunas que comprenden mezclas de cepas meningococicas multivalentes
BRPI0513200A (pt) uso de um anticorpo anti-igf-1r na preparação de um medicamento para tratamento combinado para malignidades não-hematológicas
BRPI0415249A (pt) terapia de combinação para infecção por hcv
BRPI0804623B8 (pt) uso de albumina humana terapêutica para a preparação de um fármaco para o tratamento de pacientes sofrendo de distúrbios cognitivos
BRPI0517976A (pt) métodos de tratamento
BRPI0407854A (pt) composição de vacina e método para o tratamento de um paciente que requer um reforço de sua resposta imunológica
Deo et al. Improvement in the quality of life of a patient of ectodermal dysplasia with reconstructive surgeries
BRPI0516134A (pt) neurotoxinas de clostridium para uso na cicatrização de tecidos
BR102020007149A8 (pt) Usos de um anticorpo anti-cgrp ou anti-cgrp-r ou um fragmento dos mesmos para melhorar o sintoma mais incômodo (mbs) e a impressão global de mudança (pgic) associados com enxaqueca
BRPI0412506A (pt) células autólogas que induzem à autotoleráncia de origem monocìtica e seu uso em preparações farmacêuticos
Solheim et al. Primary purulent meningococcal pericarditis with tamponade
Day Physician suicide
Dempsey Physician Suicide
McDermott Streptomycin in the treatment of tuberculosis
Hendee Physician Suicide-Reply
Parish Discussion on Active Immunization—Some Present-Day Problems
Cox et al. Airway Obstruction, Weight Loss, And Gastroparesis In An Undiagnosed Adolescent With HAE
Davies et al. Cost-effectiveness studies
Bourne Points from letters: Local corticosteroids for chronic backache
Russell The drug bill
Moore Points from letters: Disopyramide and warfarin

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: A61K 39/00 (2006.01), A61K 39/095 (2006.01), A61K

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 26/02/2019, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 16A ANUIDADE.

B24D Patent annual fee: restoration after fee payment
B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 21A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2822 DE 04-02-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.